Percheron Therapeutics Ltd
ASX:PER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kunshan Asia Aroma Corp Ltd
SZSE:301220
|
CN |
|
G
|
GFM Resources Ltd
XTSX:GFM.H
|
CA |
|
Gettop Acoustic Co Ltd
SZSE:002655
|
CN |
|
Buana Lintas Lautan Tbk PT
IDX:BULL
|
ID |
|
G
|
Guangdong Chaohua Technology Co Ltd
SZSE:002288
|
CN |
|
E
|
Electrica Puntilla SA
SGO:PUNTILLA
|
CL |
|
Deutsche Lufthansa AG
XETRA:LHA
|
DE |
|
Marathon Petroleum Corp
NYSE:MPC
|
US |
|
J
|
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
|
CN |
|
Southern Cross Gold Consolidated Ltd
TSX:SXGC
|
CA |
Percheron Therapeutics Ltd
Total Receivables
Percheron Therapeutics Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Percheron Therapeutics Ltd
ASX:PER
|
Total Receivables
AU$1.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
46%
|
CAGR 10-Years
17%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Receivables
AU$52.1k
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Receivables
AU$181.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Receivables
AU$26.5m
|
CAGR 3-Years
105%
|
CAGR 5-Years
104%
|
CAGR 10-Years
97%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Receivables
AU$10.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Percheron Therapeutics Ltd
Glance View
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
See Also
What is Percheron Therapeutics Ltd's Total Receivables?
Total Receivables
1.6m
AUD
Based on the financial report for Dec 31, 2025, Percheron Therapeutics Ltd's Total Receivables amounts to 1.6m AUD.
What is Percheron Therapeutics Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
17%
Over the last year, the Total Receivables growth was -38%. The average annual Total Receivables growth rates for Percheron Therapeutics Ltd have been 8% over the past three years , 46% over the past five years , and 17% over the past ten years .
